Comparing the Diagnostic Value of the Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in Women with an Adnexal Mass

Purpose Ovarian cancer is the fifth leading cause of cancer death among women worldwide. This study aimed to compare the diagnostic value of the risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) in women with an adnexal mass.

This cross-sectional study investigated 245 patients with adnexal mass in Afzalipour Hospital, Kerman, Iran, from 2016 to 2017. Before surgery, 10 cc of blood was taken from each patient. Tumor markers were measured using luminescence immunochemistry with HE4 and CA-125 kits. After surgery, tissue samples were sent to a medical diagnostic laboratory. World Health Organization criteria were applied for pathological classification. Based on CA-125 and HE4 levels and ultrasound findings and menopausal status of patients, ROMA and RMI were used to calculate the malignancy probability in each patient.

The average age of cases was 40.88 ± 14 years. Most tumors were benign (45%). The rate of mass metastasis was 2%. The mean levels of HE4 and CA-125 were 117.52 ± 161.49 and 160.945 ± 302.49, respectively. ROMA was more sensitive than RMI for diagnosis of malignancies, borderline and endometriosis. ROMA was of higher sensitivity and specificity for diagnosis of ovarian cancer in postmenopausal patients. Both ROMA and RMI were of higher sensitivity, specificity, positive and negative predictive values for diagnosis of malignancies.

ROMA is more sensitive than RMI for the diagnosis of ovarian cancer. Accordingly, it can be applied as an appropriate method for diagnosing ovarian cancer as well as for treatment decisions in gynecological surgery wards. Similar content being viewed by others

Muinao T, Boruah HPD, Pal M. Multi-biomarker panel signature as the key to diagnosis of ovarian cancer. Heliyon. 2019;5(12):e02826. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. Badgwell D, Bast R. Early detection of ovarian cancer. Dis Markers. 2007;23(5–6):397–410. Jayson GC, Kohn EC, Kitchener HC, et al. Ovarian cancer. The Lancet. 2014;384(9951):1376–88. Siegiel R, Miller K, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. Zhang L, Chen Y, Wang K. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Curr Probl Cancer. 2019;43(2):135–44. Hellström I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Can Res. 2003;63(13):3695–700. Sölétormos G, Duffy MJ, Hassan SOA, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European Group on Tumor Markers. Int J Gynecol Cancer. 2016;26(1):43–51. Priyanka V, Karthiga S, Sivanesan B, et al. A Comparative Study of RMI and ROMA in women presenting with an adnexal mass. Indian J Gynecol Oncol. 2018;16(1):4. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112(1):40–6. Dijmărescu AL, Gheorman V, Manolea MM, et al. Serological and immunohistochemical biomarkers for discrimination between benign and malignant ovarian tumors. Rom J Morphol Embryol. 2019;60(4):1163–74. Al-Ogaidi I, Gou H, Aguilar ZP, et al. Detection of the ovarian cancer biomarker CA-125 using chemiluminescence resonance energy transfer to graphene quantum dots. Chem Commun. 2014;50(11):1344–6. Perez BH, Gipson IK. Focus on molecules: human mucin MUC16. Exp Eye Res. 2008;87(5):400. Ferraro S, Braga F, Lanzoni M, et al. Serum human epididymis protein 4 versus carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol. 2013;66(4):273–81. Meray O, Türkçüoğlu I, Meydanlı MM, et al. Risk of malignancy index is not sensitive in detecting non-epithelial ovarian cancer and borderline ovarian tumor. J Turk German Gynecol Assoc. 2010;11(1):22. Kotowicz B, Fuksiewicz M, Sobiczewski P, et al. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages. Eur J Obstetr Gynecol Reprod Biol. 2015;194:141–6. Gizzo S, Berretta R, Di Gangi S, et al. Borderline ovarian tumors and diagnostic dilemma of intraoperative diagnosis: could preoperative He4 assay and ROMA score assessment increase the frozen section accuracy? A multicenter case-control study. Biomed Res Int. 2014;2014:803598. Nassir M, Darb-Esfahani S, Richter R, et al. HE4 tissue expression in borderline ovarian tumors: a pilot study by the tumorbank ovarian cancer network. Anticancer Res. 2013;33(4):1673–7. Al Musalhi K, Al Kindi M, Al Aisary F, et al. Evaluation of HE4, CA-125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) in the preoperative assessment of patients with adnexal mass. Oman Med J. 2016;31(5):336. Wang J, Gao J, Yao H, et al. Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis. Tumor Biol. 2014;35(6):38–127.

The authors thank the staff and participants of this study for their important contributions. Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Author information Authors and Affiliations Corresponding author Ethics declarations Conflict of interests The authors declare that they have no conflict of interests. Consent to participate Informed consent was taken from all patients. Ethics approval This study was approved by the Ethics Committee of Kerman University of Medical Sciences in Iran (Ethical Code: IR.KMU. AH.REC.1396.1553). Additional information Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Rights and permissions About this article Cite this article Honarvar, Z., Monshi, M. & Karami Robati, F. Comparing the Diagnostic Value of the Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in Women with an Adnexal Mass. Indian J Gynecol Oncolog 19, 56 (2021). https://doi.org/10.1007/s40944-021-00514-y Received: Revised: Accepted: Published: Version of record: DOI: https://doi.org/10.1007/s40944-021-00514-y